English
Incidence of Adverse and Safety Events in Individuals with Parkinson’s Disease Treated with Catechol-O-Methyltransferase Inhibitor Opicapone as an Add-On to Levodopa Treatment: A Systematic Review and Meta-Analysis
Paula Abola
George Jabishvili
Abstract
Opicapone, a once-daily catechol-O-methyltransferase (COMT) inhibitor, is used as an add-on to levodopa treatment to manage motor fluctuations in Parkinson’s Disease (PD). Although its efficacy in extending ON time is established, the safety profile of opicapone, particularly regarding adverse events and dyskinesia, remains under investigation. A systematic review and meta-analysis were performed with randomized controlled trials (RCTs) and open-label trials that investigated the incidence of adverse events in individuals with PD treated with opicapone as an add-on to levodopa treatment. The systematic search was conducted in PubMed, Cochrane, and EBSCO Megafile databases. Random-effects meta-analyses calculated risk ratios (RR) for adverse events, serious adverse events, adverse events leading to discontinuation, and dyskinesia. Certainty of evidence was assessed using the Cochrane Grading Recommendations Assessment, Development and Evaluation approach. Six studies (n = 2705) were included, with four RCTs eligible for meta-analysis. Opicapone at both 25 mg and 50 mg doses was associated with a significantly increased risk of dyskinesia compared to placebo (25 mg: RR = 2.47; 50 mg: RR = 2.75). No statistically significant differences were found for overall adverse events, serious adverse events, or adverse events leading to discontinuation. Heterogeneity across studies was generally low. Opicapone, as an add-on to levodopa treatment, shows a favorable overall safety profile, with the primary concern being an increased incidence of dyskinesia. Clinicians should monitor for motor complications and adjust levodopa dosing as needed. Further research is needed to refine dyskinesia management strategies and evaluate long-term safety outcomes.
Keywords:
Parkinson’s Disease, Opicapone, adverse events, safety eventsSimilar Articles
- Marcin Pasternak, Articaine – the queen of an infiltrative anaesthesia? A peculiar amino-amide local anaesthetic and its use in the dental practice from a pharmacological perspective , Prospects in Pharmaceutical Sciences: No. 2025 (Early Access)
- Michał Gackowski, Katarzyna Połomska, Natalia Szczucka, Mateusz Wylaź, Digital-based system as a tool for improving healthcare coordination - a perspective study , Prospects in Pharmaceutical Sciences: Vol. 22 No. 2 (2024)
- Natalia Cichoń, Dominika Lach, Joanna Saluk-Bijak, Michał Bijak, ANTICOAGULANT THERAPY IN ACUTE CORONARY SYNDROMES AND ISCHEMIC STROKE , Prospects in Pharmaceutical Sciences: Vol. 15 No. 5 (2017)
- Bartłomiej Kot, Mateusz Moczulski, Agnieszka Czajkowska, Arkadiusz Kocur, Pharmacotherapy of apnea in the premature neonatological subpopulation – therapeutic opportunities, pharmacokinetic implications and recommendations for therapeutic drug monitoring , Prospects in Pharmaceutical Sciences: Vol. 22 No. 2 (2024)
- Barbara Krzemińska, Gabriela Szewczyk, Cotoneaster horizontalis Decne. (Rosaceae) - medicinal or just ornamental species? , Prospects in Pharmaceutical Sciences: Vol. 22 No. 2 (2024)
- Szymon Barczak, Barbara Badura, Agnieszka Lembas, Tomasz Mikuła, Alicja Wiercińska-Drapało, Severe course of HIV-related Kaposi’s sarcoma with cutaneous, visceral and oral manifestations in a late-presenting patient , Prospects in Pharmaceutical Sciences: Vol. 22 No. 2 (2024)
- Dariusz Łaszczych, Aleksandra Czernicka, Kornelia Kędziora-Kornatowska, Interaction between warfarin and selected superfoods: a comprehensive review of potential mechanisms and their clinical significance , Prospects in Pharmaceutical Sciences: Vol. 22 No. 3 (2024)
- Agata Pisula, Agnieszka Sienicka, Agnieszka Dobrowolska-Redo, Joanna Kacperczyk-Bartnik, Ewa Romejko-Wolniewicz, PARP inhibitors in ovarian cancer therapy , Prospects in Pharmaceutical Sciences: Vol. 22 No. 2 (2024)
- Paweł Żero, Maria Niemyjska, Magdalena Rasztawicka, Dorota Maciejewska, BREAST CANCER DISEASE AND NEW COMPOUNDS WITH ANTICANCER ACTIVITY , Prospects in Pharmaceutical Sciences: Vol. 3 No. 2 (2005)
- Paulina Wilczyńska, Barbara Lisowska-Myjak, ROLA AMINOPEPTYDAZ ŁOŻYSKOWYCH W PRZEBIEGU CIĄŻY , Prospects in Pharmaceutical Sciences: Vol. 17 No. 1 (2019)
You may also start an advanced similarity search for this article.
Details
References
Statistics
Authors
Citation rules
Cited by / Share
Licence
This work is licensed under a Creative Commons Attribution 4.0 International License.